葛根素注射液对冠心病稳定型心绞痛患者超敏C反应蛋白、肿瘤坏死因子α的影响及疗效

The influence of Puerarin injection on the levels of serum hs-CRP and TNF-α of patients with stable angina pectoris and its clinical outcomes of treatment

目的:观察葛根素注射液对冠心病稳定型心绞痛患者高敏反应蛋白的(Hs-CRP)、肿瘤坏死因子(TNF-α)的影响及其临床治疗效果。方法随机将76例冠心病稳定型心绞痛患者分为两组,治疗组39例采用常规治疗加葛根素注射液治疗;对照组37例,采用常规治疗加丹参注射液治疗,分别于治疗前和治疗后采集空腹肘静脉血,测定血清Hs-CRP、TNF-α水平,同时观察并记录患者临床症状、心电图、心率及血压变化情况。结果:治疗组的临床总有效率为79.5%,明显高于对照组的54.1%(P<0.05),心电图的改善情况亦明显优于对照组(P<0.01),其减慢心率作用优于对照组(P<0.05),治疗组用药后与治疗前及对照组治疗后比较其血清hs-CRP、TNF-α水平明显降低(P<0.05)。结论:葛根素注射液能降低患者血清hs-CRP、TNF-α水平,能显著改善患者临床症状及心电图表现,能减慢心率,从而延缓动脉粥样硬化进程,这可能是其治疗冠心病的机理之一。

Objective：To observe the influence of Puerarin injection on the levels of serum hs-CRP and TNF-α of patients with stable angina pectoris and its clinical outcomes of treatment.Methods： 76 patients with stable angina pectoris were divided into two group randomly： in Puerarin injection treatment group 39 cases,in control group 37 cases.Respectively fasting venous blood was collected from the each group before and after treatment,the levels of serum hs-CRP and TNF-α were detected At the same time we observed and recorded the changes of clinical symptoms,ECG,heart beats and blood pressure.Results： The total efficiency in Puerarin injection group was 79.5% which was significantly higher than that in control group（P〈0.05）,the levels of serum hs-CRP and TNF-α in the Puerarin injection group were significantly lower than those in control group（P〈0.05）,there were no differences of serum hs-CRP and TNF-α between before and after control group treatment,the role of reducing heart beats and the changes of ECG in Puerarin injection group were significantly better than those in control group（P〈0.05,P〈0.01）.Conclusion：Puerarin injection can effectively reduce the levels of serum hs-CRP and TNF-α,and it can improve the clinical symptoms and the ECG changes of patients with stable angina pectoris,and it can reduce heart beats,which inhibit inflammation of atherosclerosis,this is probably one of the mechanism of treatment of coronary heart disease.